Jun 07, 2023 / 08:00PM GMT
Andrew Tsai - Jefferies - Analyst
Okay, we're going to get started on the next session. I'm Andrew Tsai -- hi, everyone -- senior biotech analyst here at Jefferies. And I'm joined by John Valliant, CEO of Fusion.
Welcome, John.
John Valliant - Fusion Pharmaceuticals Inc. - CEO
Thank you.
Questions and Answers:
Andrew Tsai - Jefferies - AnalystAnd I think we have 25 minutes for our fireside chat. So, John, to start -- maybe to begin, maybe give us a brief overview of Fusion and -- what is your differentiation versus some of the players out there, in your view? What can you do that others cannot? And then maybe talk about your news flow over the next six to 12 months.
John Valliant - Fusion Pharmaceuticals Inc. - CEO
Sure, Andrew. Happy to. Thanks for everyone joining.
So Fusion is focused on creating next-generation radiopharmaceuticals and, more specifically, targeted alpha therapies. So the general premise of the technology is to connect an alpha